Want to see AEMD full AI Analyst Report?
AEMD Stock Chart & Stats
$2.40
>-$0.01(-0.43%)
At close: 4:00 PM EDT
$2.40
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$1.71 - $79.00
Previous CloseN/A
Volume26.32K
Average Volume (3M)2.13M
Market Cap
$1.31M
Enterprise Value-$2.98
Total Cash (Recent Filing)$4.93M
Total Debt (Recent Filing)$255.05K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 18, 2026EPS Estimate
-2.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.70
Shares Outstanding711,136
10 Day Avg. Volume6,274,041
30 Day Avg. Volume2,127,084
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.51
Price to Sales (P/S)0.00
P/FCF Ratio-1.05
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.50Price Target Upside-37.50% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-8.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressionProgress into the final cohort provides a defined path toward completing the current oncology study. Continued absence of device-related serious safety events supports development credibility, although efficacy remains unproven.
Potentially Broad Platform ApplicabilityResearch across multiple disease areas increases the platform's potential addressable use cases beyond oncology. The Hemopurifier's ability to target circulating extracellular vesicles could support future partnerships or indication expansion.
Cost Control And Near-term LiquidityLower expenses and additional financing extend the time available to generate clinical data and pursue regulatory discussions. This improves near-term execution capacity, though the runway still depends on disciplined spending and future funding.
Bears Say
No Established Commercial RevenueThe absence of recurring product revenue means Aethlon has not demonstrated commercial demand or operating leverage. Future financial performance remains dependent on successful development, regulatory progress and eventual commercialization.
Persistent Cash Burn And Financing DependenceCash-based losses consume resources needed for trials and product development, limiting strategic flexibility. Additional equity, partnerships or grants will likely be needed for larger studies, creating execution risk and potential dilution.
Limited Evidence And Development ConstraintsSmall samples and pending analysis leave uncertainty about reproducibility, clinical benefit and regulatory acceptance. Multi-hour treatments that are difficult to intensify could also constrain trial design, adoption and the scalability of any eventual therapy.
Aethlon Medical News
AEMD FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was $1.71 and its highest was $79.00 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is $1.31M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Nov 18, 2026 which is in 76 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Aug 13, 2026. The company reported -$4.02 earnings per share for the quarter, missing the consensus estimate of -$3.925 by -$0.095.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -2.7.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 711,136 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -$4.02 in its last earnings report, missing expectations of -$3.925. Following the earnings report the stock price went down -3.413%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in AEMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
AEMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.View all AEMD earnings summariesAEMD Stock 12 Month Forecast
Average Price Target
$1.50
▼(-37.50% Downside)
Technical Analysis
Ownership Overview
12.67% Insiders
0.97% Mutual Funds
― Other Institutional Investors
86.37% Public Companies and
Individual Investors